Compliance · State rules

Office-use compounding in Arizona

Veterinary only - human office use ended September 5, 2026

USPeptideRx EditorialLast reviewed: October 2, 2026

Arizona’s pharmacy compounding rule changed on September 5, 2026. From that date, A.A.C. R4-23-410(F) lets a pharmacy provide a compounded product only to a veterinarian, and no human office-use pathway survives. For the window ending September 4, 2026, R4-23-410(B)(3) allowed a compounded product to be provided to a medical practitioner to administer to that practitioner’s patient, under a two-legend label. The earlier provision is quoted below as historical text; the veterinary-only provision applies from September 5, 2026.

The governing rule

Arizona’s office-use position is set by A.A.C. R4-23-410(B)(3) to September 4, 2026; R4-23-410(E)–(F) from September 5, 2026. The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

A.A.C. R4-23-410(B)(3) — the rule for the window ending September 4, 2026

3. Neither the pharmacy permittee nor a pharmacist employed by the pharmacy permittee provides a compounded pharmaceutical product to a pharmacy, medical practitioner, or other person for dispensing or distributing except that a compounded pharmaceutical product may be provided to a medical practitioner to administer to a patient of the medical practitioner if each container is accompanied by the written list required in subsection (I)(5) and has a label that includes the following: a. The pharmacy’s name, address, and telephone number; b. The pharmaceutical product’s name and the information required in subsection (I)(4); c. A lot or control number; d. A beyond-use-date based upon the pharmacist’s professional judgment, but not more than the maximum guidelines recommended in the Pharmacy Compounding Practices chapter of the official compendium unless there is published or unpublished stability test data that shows a longer period is appropriate; e. The statement "Not For Dispensing;" and f. The statement "For Office or Hospital Administration Only."

A.A.C. R4-23-410(F) — the rule from September 5, 2026 (File No. R26-122)

F. A pharmacy permittee or pharmacist shall not provide a compounded pharmaceutical product to a pharmacy, medical practitioner, or other person unless the medical practitioner is a veterinarian who will administer the compounded pharmaceutical product to a patient of the veterinary medical practitioner. The permittee or pharmacist who provides a compounded pharmaceutical product to a veterinary medical practitioner shall ensure the compounded pharmaceutical product is labeled with the following information: 1. The name, address, and telephone number of the compounding pharmacy; 2. The compounded pharmaceutical product’s name; 3. A lot or control number; 4. A beyond-use date consistent with the information in subsection (B); 5. An indication the pharmaceutical product has been compounded; and 6. The following statement: Not for Dispensing; For Veterinary Use Only.

A.A.C. R4-23-410(E) — from September 5, 2026, naming (F) as the sole exception

E. A pharmacist may compound a pharmaceutical product for which the pharmacist does not have a prescription order if ... the pharmacist reasonably anticipates receipt of a prescription order ... The pharmacist shall ensure a pharmaceutical product compounded under this subsection is labeled accurately and stored in a manner that protects the pharmaceutical product’s quality until the pharmaceutical product is dispensed under a patient-specific prescription order except as described in subsection (F) when the pharmaceutical product is dispensed to a veterinary medical practitioner. A pharmacist shall not add an ingredient to a pharmaceutical product that was compounded at another 503A facility.

A.R.S. § 32-1901(11) — the statutory definition of compounding

"Compounding" means preparing, mixing, assembling, packaging or labeling a drug ... for the purpose of dispensing to a patient based on a valid prescription order. Compounding includes preparing drugs in anticipation of prescription orders ... or for administration by a medical practitioner to the medical practitioner’s patient and not for sale or dispensing. Compounding does not include ... preparing drugs for sale to pharmacies, practitioners or entities for the purpose of dispensing or distribution.

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

Update - September 5, 2026Medium confidence: The amendment described on this page has taken effect. As of September 5, 2026, A.A.C. R4-23-410(F) bars a pharmacy permittee or pharmacist from providing a compounded pharmaceutical product to a pharmacy, medical practitioner or other person unless that practitioner is a veterinarian who will administer it to a veterinary patient. The earlier provision at R4-23-410(B)(3), which allowed a compounded product to be provided to a medical practitioner to administer to that practitioner’s patient under the "Not For Dispensing" and "For Office or Hospital Administration Only" legends, is no longer in force. It is quoted below as the rule that governed through September 4, 2026, and the veterinary label from this date reads "Not for Dispensing; For Veterinary Use Only."This update applies the effective date and rule text recorded in the cited Register notice, File No. R26-122. The codified Title 4, Chapter 23 PDF retrieved for this update was still Supp. 26-1 (March 31, 2026), where subsection (F) concerns equipment and utensils. The amended subsection (F) could not be re-confirmed in that supplement.
The date, and where it is publishedHigh confidence: September 5, 2026. Published at 32 A.A.R. 1648-1658, Volume 32, Issue 30, July 24, 2026, as File No. R26-122. Preamble item 4 states the effective date in those terms. The Governor’s permission to proceed under A.R.S. § 41-1039 was granted May 8, 2026.
Why the change is easy to missHigh confidence: The Board’s stated justification never mentions removing human office use. The preamble frames the rewrite as aligning with the updated USP chapters and with federal law. The repeal is in the rule text, not in the summary, so anyone reading the preamble alone would miss it entirely.
Two independent confirmations that no human pathway survivesHigh confidence: First, the new subsection (E) names subsection (F) as the sole exception to patient- specific dispensing, and (F) is veterinarian-only. Second, across the entire published notice the word "administer" appears only in the struck old text and in the new veterinary subsection.
Veterinarians were already inside the earlier ruleHigh confidence: "Medical practitioner" is defined at A.R.S. § 32-1901(56) to include veterinarians, so the rule in force to September 4, 2026 already covered them. The September 5, 2026 change did not add a veterinary pathway; it removed everyone else from the existing one.
The label legends, on both sides of the dateHigh confidence: For the window ending September 4, 2026 the label carried two legends: "Not For Dispensing" and "For Office or Hospital Administration Only." From September 5, 2026 the veterinary label carries "Not for Dispensing; For Veterinary Use Only."
Quantity — the cap is structural, not a percentage in the pharmacy rulesHigh confidence: There is no percentage or day-supply cap in the pharmacy rules. A.R.S. § 32-1981(5)(d) excludes from "wholesale distribution" the sale of prescription drugs by a pharmacy, not to exceed five percent of the pharmacy’s gross sales, to practitioners for office use. Exceeding that figure strips the exemption and makes the pharmacy a wholesale distributor, requiring a full-service wholesale permit with a bond, a designated representative and fingerprint clearance.This is a wholesale-permit exemption, not a compounding authorisation — it answers whether a permit is needed, never whether the product may be compounded without a prescription. Because it covers prescription drugs generally rather than compounded ones, sales of manufactured products for office use appear to survive the September 5, 2026 rule change, subject to the five-percent figure. That last point is medium-high.
Sterile and non-sterile alikeHigh confidence: R4-23-410 governs all compounding and draws no sterile distinction for office-use purposes. The sterile rule R4-23-670 contains no office-use provision at all, before or after the amendment — the legend "For Office or Hospital Administration Only" appeared in the rule that governed through September 4, 2026, at R4-23-410(B)(3). R4-23-675(E) routes limited- service sterile pharmacies back to R4-23-410, so the September 5, 2026 prohibition reaches sterile compounders too.
Administer-onlyHigh confidence: Explicit in both versions. The rule in force to September 4, 2026 barred providing product "for dispensing or distributing", permitted it only "to administer", and mandated the "Not For Dispensing" legend. The version from September 5, 2026 carries the same restriction inside the veterinary pathway.
Recordkeeping tightensHigh confidence: Seven years in both versions (R4-23-410(K)(1)). From September 5, 2026 a new subsection (N) requires records to be made available to the Board or the Board’s designee within three business days of a request.No affirmative periodic reporting to the Board for office-use activity was found, which is a medium-high finding rather than a high one.
The federal conditioning tightens sharplyHigh confidence: The rule in force to September 4, 2026 required compliance with "applicable federal and state law". From September 5, 2026 the new R4-23-410(B) incorporates federal law by reference: USP 795, 797, 800 and 825, together with 21 U.S.C. § 353a (2024 edition), for permittees compounding under section 503A. For outsourcing facilities it incorporates 21 CFR Parts 210, 211 and 212 with 21 U.S.C. § 353b.
A new provision aimed at platform prescribingHigh confidence: From September 5, 2026 the new subsection (H) codifies the essentially-a-copy limits, including the requirement of a clinically significant difference for a specifically identified patient. Subsection (H)(2) bars filling copy prescriptions submitted "through a pharmacy platform or electronic system" without patient-specific clinical information — aimed squarely at telehealth and platform prescribing.
Anti-kickback, and it is a permit-level sanctionHigh confidence: A.R.S. § 32-1930(B): the Board "shall deny or revoke a pharmacy permit if a medical practitioner receives compensation, either directly or indirectly, from a pharmacy as a result of the practitioner’s prescription orders." Directly relevant to any rebate, volume-incentive or referral arrangement.
Nonresident pharmaciesHigh confidence: R4-23-607(A), amended effective August 30, 2025, requires both an Arizona nonresident pharmacy permit and a current equivalent licence in the home jurisdiction. Subsections (E)(1)(c) and (d) require holding a copy of each Arizona purchaser’s current licence, producible within two business days. It is a permit rule and does not override the prohibition that took effect September 5, 2026.
An emergency carve-out that is not an office-use pathwayHigh confidence: A.R.S. § 32-1910(F)–(G) lets health-system-owned pharmacies compound or repackage on a non-patient-specific basis for that health system’s patients during a declared emergency, and the authority ends when the declared state of emergency is terminated. It is not office-use authority and should not be cited as such.
A statute-and-rule tension from September 5, 2026Medium confidence: As fetched 28 August 2026, Section 32-1901(11) describes compounding as including preparation for administration by a medical practitioner, and § 32-1981(5)(d) exempts office-use sales up to five percent of gross sales — while, from September 5, 2026, R4-23-410(F) forbids providing compounded product to any practitioner who is not a veterinarian.Flagged, not resolved. A statutory definition and a wholesale exemption are weak bases for defying an express Board prohibition, so the rule should be treated as controlling.
An ambiguity in the statutory definitionMedium confidence: The phrase "and not for sale or dispensing" in § 32-1901(11) is undefined. The defensible reading is that the practitioner may not sell or dispense the product, but a Board could read "not for sale" as restricting the pharmacy’s sale. Do not assert that selling office stock is unambiguously authorised by the statute.No interpretive authority construing the phrase was found.
The rulemaking trailHigh confidence: Docket at 31 A.A.R. 2637 (August 8, 2025); notice of proposed rulemaking at 31 A.A.R. 2619 (August 8, 2025); supplemental notice at 31 A.A.R. 4565 (December 19, 2025); Governor’s permission May 8, 2026; published July 24, 2026; effective September 5, 2026. Commenters included a national pharmacy chain, pharmaceutical manufacturers, a compounding trade association and a patient advocacy organisation.
Last changeHigh confidence: The amendment took effect September 5, 2026. The provision it replaced, R4-23-410(B)(3), was last substantively amended December 4, 2006 and is codified in the supplement covering rules filed through March 31, 2026.

Arizona at a glance

Arizona office-use compounding summary, reviewed 2026-10-02
Human office use	Ended September 5, 2026 - veterinary only
Sterile preparations	No distinction; the change reaches sterile compounders too
Quantity cap	5% of gross sales — a wholesale-permit exemption, not a permission
Mandatory label legend	Not for Dispensing; For Veterinary Use Only
Board reporting	None routine; 3-business-day record production from Sept 5, 2026
Last change	Effective September 5, 2026 (File R26-122)
Governing rule	A.A.C. R4-23-410(B)(3) to September 4, 2026; R4-23-410(E)–(F) from September 5, 2026

Receiving 503B office stock in Arizona

Arizona has no outsourcing-facility category at all — a 503B is permitted as a drug manufacturer — and it asks for two credentials rather than one. The 503B channel is also the one that was untouched by the rule change that took effect on 5 September 2026.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Arizona asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence: Two credentials, and both are required. A.A.C. R4-23-607(A) bars a non-resident from selling or distributing prescription-only drugs into Arizona without possessing both "a current Board-issued nonresident pharmacy permit, nonresident manufacturer permit, or nonresident full-service or nonprescription drug wholesale permit" and "a current equivalent license or permit issued by the licensing authority in the jurisdiction where the person resides." The strings "outsourcing" and "503B" appear zero times in the chapter; the manufacturer permit is the fit.R4-23-607(E)(2)(a) expressly names "a medical practitioner currently licensed under A.R.S. Title 32" as a lawful recipient, and (E)(2)(c) puts the verification burden on the shipper, which must keep a copy of each Arizona buyer’s current licence. Whether a separate wholesale permit is also required is the one genuinely uncertain licensure point.
Does your practice need a permit?High confidence: No pharmacy-board facility permit. The permit list at A.R.S. § 32-1930(A)(1) is closed and contains no clinic category, and § 32-1921(A)(5) provides that the chapter does not prevent health professionals "from dispensing or personally administering drugs or devices to a patient for a condition being treated by the health professional".
Administer vs dispenseLow confidence: Unresolved in Arizona, and published here as unresolved. A.R.S. § 32-1491(H) defines dispense to include "administering" as a step ancillary to delivery, while § 32-1921(A)(5) treats dispensing and personally administering as two distinct acts. No Arizona agency guidance resolving it was reachable. Do not assume that administering office stock sits outside the § 32-1491 dispensing registration.
Scheduled (controlled) stockHigh confidence: No separate Arizona controlled-substance licence — § 36-2522(A) requires a Title 32 licence plus DEA registration. CSPMP registration is mandatory for every DEA-registered Arizona practitioner under R4-23-501(A), but § 36-2608(F)(1) exempts from reporting "a controlled substance that is administered directly to a patient".

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Federal law is a second, independent constraint — a state prohibition is not the only thing standing in the way. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Arizona compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

This page describes the rule change effective September 5, 2026, using the cited Register notice. Everything described as applying to the window ending September 4, 2026 is historical. The codified PDF retrieved for this update still contained the earlier rule; confirm the amended text of R4-23-410 before acting.
We could not sweep the legislature bill by bill: the bill search is script-driven and the text endpoint returned an access error. The statutes cited were fetched live and are the currently published versions, but we cannot tell you affirmatively that no 2026 session law altered §§ 32-1901 or 32-1981.
We located no Board guidance interpreting office use. The Board’s site exposes no minutes or policy-statement archive, and its own summary of statute and rule changes covers only 2005 to 2024.
Arizona case law and disciplinary decisions construing R4-23-410(B)(3) are outside the scope of this page; we have not searched them.
Beyond the primary sources cited here, we have not surveyed board newsletters, declaratory statements, enforcement actions, disciplinary orders or coverage of pending bills. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.